Osteosarcoma.

Significant advances are being made in the treatment of osteosarcoma and improvement in the five year survival is being reported. Active study of the etiology, pathogenesis, immunology, immunotherapy, radiotherapy, chemotherapy, and surgical management is currently in progress. The preliminary survival statistics with adjuvant chemotherapy or immunotherapy are encouraging and it is hoped that these survival figures will be maintained with further follow-up. Our experience suggests that, when practical, patients with osteosarcoma should be treated in or in cooperation with centers actively involved in the evaluation of osteosarcoma therapy. Not only does this step offer the patient optimal opportunity to receive the most current therapy, but it is essential in obtaining adequate numbers of patients for critical analysis.